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Abstract
Background: HX575 is a human recombinant epoetin alfa that was approved for use in Europe in
2007 under the European Medicines Agency biosimilar approval pathway. Therefore, in order to
demonstrate the bioequivalence of HX575 to an existing epoetin alfa, the pharmacokinetic and
pharmacodynamic response to steady state circulating concentrations of HX575 and a comparator
epoetin alfa were compared following multiple intravenous administrations.
Methods: An open, randomised, parallel group study was conducted in 80 healthy adult males.
Subjects were randomised to multiple intravenous doses of 100 IU/kg body weight of HX575 or of
the comparator epoetin alfa three-times-weekly for four weeks. Serum epoetin concentrations
were measured using an enzyme-linked immunosorbent assay and pharmacokinetic parameters for
the two treatments were compared. The time course and area under the effect curve ratio of
haematological characteristics were used as surrogate parameters for efficacy evaluation.
Results: The haematological profiles of both treatments were similar, as determined from their
population mean curves and the AUECHb ratio and 90% confidence interval (99.9% [98.5–101.2%]),
the primary pharmacodynamic endpoint of this study. The pharmacokinetic parameters after the
treatments showed minor differences after single dosing, but not at steady state doses. After
multiple doses, HX575 was bioequivalent to the comparator with respect to the rate and extent
of exposure of exogenous epoetin (AUCτ ratio and 90% confidence interval: 89.2% [82.5–96.2%]).
Study medication was well tolerated with no clinically relevant differences between safety profiles
of the treatments. Anti-epoetin antibodies were not detected.
Conclusion:  HX575 and the comparator epoetin alfa were bioequivalent at steady state
circulating drug concentrations with respect to their pharmacokinetic profile and
pharmacodynamic action. This supports the conclusion that HX575 and the comparator epoetin
alfa, when administered intraveneously, will be equally efficacious and may be interchangeable as
therapy.
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Background
Epoetin is a glycoprotein that stimulates red blood cell
(RBC) production [1]. Patients with chronic renal failure
have impaired epoetin production, which is the primary
cause of their anaemia [2,3]. Human recombinant epoe-
tin or erythropoiesis stimulating agents (ESA) has been
shown to stimulate erythropoiesis in anaemic patients
with chronic renal failure, both in those who do, and
those who do not, require regular dialysis [3-12]. ESA are
indicated for treatment of chemotherapy-induced anae-
mia in cancer patients, and to reduce the need for allo-
genic blood transfusions in patients with moderate
anaemia scheduled to undergo elective surgery [13-15]. In
addition, human recombinant epoetin is indicated for
patients at high risk for perioperative transfusions with
significant, anticipated blood loss.
The aim of this study was to estimate the relative bioavail-
ability and pharmacodynamics of HX575 versus the com-
parator epoetin alfa at steady state drug concentrations
following multiple intravenous administration. The phar-
macokinetic profile of epoetin and the haematological
effects on haemoglobin were evaluated as a surrogate for
the therapeutic efficacy. The primary objective was to
assess bioequivalence for the area under the effect curve
(AUEC) of haemoglobin. Furthermore, the safety profiles
of the two treatments were compared. This article reports
the pharmacokinetic, pharmacodynamic and safety data
for HX575 and a comparator epoetin alfa.
Methods
This open, randomised, parallel group study enrolled 80
healthy male volunteers. Eligible subjects were 18–45
years of age, weighing 50–100 kg, physically and mentally
healthy as confirmed by an interview, medical history,
and clinical and laboratory examination. Other inclusion
criteria were: a body mass index of 19–28 kg/m2; haemo-
globin (Hb) concentrations of 13–15 g/dL; the percentage
reticulocytes (Ret, percentage of red blood cells in the
reticulocyte stage) ≤ 3% at screening; and normal, or only
minor deviation in, iron parameters (iron deficiency was
defined as ferritin < 10 ng/mL or Fe/TIBC ratio (transferrin
saturation) < 12%). Subjects had to be non-smokers or
moderate smokers (≤ 10 cigarettes/day) and abstain from
alcohol for 48 h prior to each dose administration. Only
male subjects were enrolled in order to minimise inter-
subject variability.
Subjects were not eligible if their medical history showed
evidence of pre-existing clinically significant cardiac dis-
ease or any of the following: clinically significant abnor-
malities that might influence the metabolism or excretion
of the active agent under investigation; increased values
(above upper limit of normal range) of reticulocytes,
erythrocytes, platelets or serum potassium; baseline
serum epoetin level < 30 mIU/mL; use of systemic andro-
gens within two months prior to study start; use of any
medication (including over-the-counter treatments) that
was not expressively permitted within two weeks prior to
study start; epoetin therapy within eight weeks before
study start.
An iron supplement (100 mg twice-daily) was adminis-
tered to all subjects during the study. Except for paraceta-
mol, all other concomitant use of drugs was restricted.
The study was conducted in accordance with the Declara-
tion of Helsinki, Good Clinical Practice and Good Labo-
ratory Practice. The study was approved by an
independent ethics committee and all volunteers gave
their written informed consent.
Eligible subjects were randomised to receive an intrave-
nous injection of one of two different treatments three-
times-weekly for 4 weeks. HX575 treatment consisted of
injections of 100 IU/kg body weight of human recom-
binant epoetin alfa (HX575, Binocrit®, Sandoz Pharma-
ceuticals GmbH, Germany). The comparator treatment
consisted of injections of 100 IU/kg body weight of epoe-
tin alfa (Erypo®/Eprex®, Ortho Biotech, Germany). Both
groups received an intravenous injection delivered over a
1 minute period on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22,
24 and 26. Both HX575 and the comparator epoetin alfa
were supplied as 10,000 IU/mL formulations. Subjects
fasted for at least 8 h prior to and 2 h after administration.
Blood sampling
For Ret count, RBC count, Hb concentrations and
haemoatocrit (HCT), blood samples of 2.6 mL were
drawn: on day 1 at 30, 20, 10 min pre-dose and just before
dosing, on days 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26
just before dosing, and on day 29 at 72 h after the last
dose. For determination of transferrin, transferrin recep-
tor, ferritin and serum iron concentrations, venous blood
samples of 12 mL were drawn on days 1, 12, 19 and 26 at
the time of dosing. For anti-epoetin antibodies assays in
serum, a blood sample of 3 mL was drawn on days 1, 15
and 29 at the time of dosing. For serum epoetin assays,
blood samples of 4 mL were drawn: at 30, 20, and 10 min
predose, just before dosing, and at 5, 10, 15, 20, 30, 45
min and 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h after the first
dosing on day 1; on days 8, 15, 19 and 22 at the time of
dosing; and at 30, 20, 10 and 0 min before dosing, and at
5, 10, 15, 20, 30, 45 min and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12,
16, 24 and 36 h after dosing on day 24.
All sample analyses were performed in the same laborato-
ries. Ret count, RBC count, Hb concentrations and HCT
were analysed at LPT Laboratory for Pharmacology and
Toxicology KG, Hamburg, Germany. Transferrin, ferritinBMC Clinical Pharmacology 2009, 9:10 http://www.biomedcentral.com/1472-6904/9/10
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and serum iron were determined at MDS Pharma Services
Central Lab GmbH, Hamburg, Germany. Transferrin
receptor was determined at Dres. Fenner & Partner, Ham-
burg, Germany. Serum anti-epoetin antibodies were
measured at Hexal Biotech Forschungs GmbH, Oberh-
aching, Germany. Serum epoetin concentration measure-
ments were performed at GTF, Gesellschaft für
Therapeutische Forschung mbH, Nürnberg-Heroldsberg,
Germany.
Pharmacokinetic assay and evaluation
The concentrations of epoetin in human serum were
determined using an enzyme immunoassay kit (EPO-
ELISA, Medac GmbH, Germany). The procedure was vali-
dated according to international guidelines. During sam-
ple analysis, the standard curve was linear between 2.5
mIU/mL and 160.0 mIU/mL for all sequences and the
lower limit of quantification for epoetin was 2.5 mIU/mL.
Samples expected to exceed the upper limit of the linear
range were diluted before analysis with diluent of the
enzyme immunoassay kit. The inter-day precision of the
control standard of epoetin in human serum was 11.4%.
Pharmacokinetic variables were calculated by non-com-
partmental analysis using actual data of endogenous epo-
etin. The primary pharmacokinetic parameter was the
epoetin AUCτ calculated over a period of 0–36 h. Second-
ary parameters were AUC0–12, Cmax, tmax, t1/2, Cmax, ss, and
Ctrough. The treatments were considered to be bioequiva-
lent when the ratio (HX575/comparator) and the 90%
confidence interval (CI) for AUCτ, Cmax, ss, Ctrough, and t1/2
(multiple dose analysis) fell within the acceptance range
of 80–125%.
Pharmacodynamic analyses
The time courses of Hb, RBC, HCT and Ret count were
used as surrogate parameters for efficacy. The pharmaco-
dynamic action of epoetin was determined as the area
under the total effect curves during 12 dosage intervals in
4 weeks for Hb, RBC, HCT and Ret count, which were cal-
culated by linear trapezoidal integration. The AUECHb was
considered the primary variable. The formulations were
considered to be bioequivalent if the 90% CI of the
AUECHb ratio fell within a range of 96.8–103.2%. The
rationale for this acceptance range was the following:
based on results from a pilot study, the Hb concentration
was estimated to change by about 3 g/dL within 4 weeks
of the multiple dose regimen of the present study. A dif-
ference between the treatments of ± 1 g/dL is considered
acceptable, since under clinical conditions tight monitor-
ing of the Hb concentrations is mandatory and no dose
adjustment for epoetin is required if the Hb concentra-
tions are stable within a range of ± 1 g/dL. Furthermore, in
clinical studies a threshold of -1.0 g/dL Hb has been used
as the greatest clinically acceptable difference to demon-
strate non-inferiority [16]. The baseline Hb concentration
in healthy volunteers was expected to be approximately
14 g/dL. Thus, the expected concentrations at the end of 4
weeks of treatment were approximately 17 ± 1 g/dL. This
corresponds to an AUECHb of (14+17 ± 1)/2 = 15.5 ± 0.5
month*g/dL. The absolute deviation of ± 0.5 from the
mean 15.5 translated into a relative acceptable difference
for the ratio of (0.5/15.5)*100% = 3.2%, which led to the
corresponding acceptance boundaries for the ratio of
96.8–103.2%. For the AUEC ratios (HX575/comparator)
and 90% CI of RBC, HCT, and Ret count, no acceptance
ranges were derived. Nevertheless, the AUEC ratios and
90% CI were compared in an exploratory fashion with the
standard bioequivalence range of 80–125%. Additionally,
the time courses of transferrin receptor, transferrin, ferri-
tin and iron concentrations were investigated.
Detection of anti-rhEPO antibodies
Sera were screened for the presence/absence of anti-
rhEPO antibodies using a radioimmuno-precipitation
(RIP) assay that was comprehensively validated according
to the requirements of the FDA guideline for bioanalytical
methods validation [17] and according to ICH guidelines
[18,19].
Safety
Adverse events were obtained from spontaneous report-
ing by the subjects or from responses to non-leading ques-
tions from the clinical staff.
Statistical methods
Sample size was determined as follows. An inter-individual
coefficient of variation of approximately 30% was expected
for the (log-transformed) AUECHb [20]. A minimum of 36
subjects per treatment group had to complete the study in
order to determine the relative pharmacodynamic effi-
ciency in terms of the AUEC ratio (HX575/comparator)
with adequate precision in an analogous way to a bioequiv-
alence study; the 90% CI of the AUECHb ratio should fall
within a range of 96.8–103.2% with a power of > 80%, pro-
vided the true ratio was 100%. For the pharmacokinetic
variable AUCτ, a coefficient of variation of 20–25% was
expected [21]. The precision of the estimate of the AUCτ
ratio thus was expected to be higher than for the AUECHb
and the sample size was not expected to be critical.
The mean, standard deviation, coefficient of variation,
range and median were calculated for each parameter. The
geometric mean (GeoM) and the coefficient of variation
of the geometric mean (GeoCV) were also determined for
concentration related parameters. For AUEC and Ctrough
the parametric point estimators for the ratio and the
shortest 90% CIs were calculated using the LSMEANS and
the root of residual mean squares from the ANOVA of log-
transformed data with subsequent exponential transfor-BMC Clinical Pharmacology 2009, 9:10 http://www.biomedcentral.com/1472-6904/9/10
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mation [22]. For parameters for which the assumption of
normally distributed data was rejected, nonparametric
point estimators for the ratios of expected medians of the
treatments and the corresponding nonparametric 90%
CIs were calculated based on the Mann-Whitney-Wil-
coxon statistics using log-transformed data [23,24]. For
tmax, the nonparametric point estimator and the nonpara-
metric 90% CIs for the difference of expected medians
were calculated according to the Mann-Whitney-Wil-
coxon statistics using the untransformed data.
Results
Eighty healthy adult males were enrolled: 40 subjects per
treatment. Seventy-six subjects completed the study and
were available for pharmacodynamic and pharmacoki-
netic evaluations. The HX575 treatment group was com-
prised of 37 subjects and the comparator treatment group
was comprised of 39 subjects. For the single dose analysis,
29 subjects in the comparator treatment group were ana-
lysed, because of the accidental administration of a lower
dose in ten subjects at the first application.
Four subjects withdrew from the study: three receiving
HX575 treatment and one receiving the comparator treat-
ment. Three subjects withdrew due to adverse events (two
subjects receiving HX575 and one receiving the compara-
tor treatment) and for one subject (HX575 treatment) the
study was stopped on day 2 due to significant deviations
from the normal range of his haematological baseline val-
ues on day 1. Demographic data of enrolled subjects are
presented in Table 1.
Pharmacokinetics
The mean (± SD) pre-dose endogenous epoetin concen-
tration was 8.5 ± 2.4 mIU/mL in the HX575 group and 7.6
± 1.7 mIU/mL in the comparator group. There were small
differences between the two treatments in the concentra-
tion-versus-time profiles after a single epoetin dose. Mean
epoetin concentrations reached their maxima of 1953 ±
621.2 mIU/mL (HX575) and 2121 ± 505.9 mIU/mL
(comparator) within 5 min after the first administration.
The mean epoetin plasma concentration had increased by
1944 ± 21.4 IU/mL (HX575) and 2113 ± 505.8 mIU/mL
(comparator) from baseline. Twelve hours after the first
application, the mean concentrations had dropped to
214.8 ± 77.8 mIU/mL (HX575) and 242.7 ± 71.5 mIU/mL
(comparator). The mean trough concentrations after mul-
tiple doses of epoetin (Table 2) were similar to the pre-
dose baseline concentrations. There was no accumulation
and the baseline concentrations appeared almost negligi-
ble in relation to the peak concentrations. The AUC0–12
after HX575 was approximately 18% lower than after the
comparator (GeoM (GeoCV) 8098 mIU/mL*h (44.5%)
after HX575 and 9903 mIU/mL*h (33.3%) after the com-
parator).
The concentration-versus-time profiles after multiple
applications of epoetin were similar for the two treat-
ments (Figure 1). Five minutes after injection, the mean
epoetin concentrations reached their peaks (Table 2),
which differed by only 3% between both treatments.
Mean epoetin levels had increased with 2181 ± 393.5
mIU/mL (HX575) and 2254 ± 421.9 mIU/mL (compara-
tor). The epoetin concentrations had decreased almost to
the initial baseline at 36 h after the eleventh application
(13.8 ± 23.1 mIU/mL (HX575) and 11.1 ± 4.0 mIU/mL
(comparator)). The AUCτ, calculated over a time period of
0–36 h, was approximately 10% lower after HX575 than
after the comparator (Table 2). The estimates of the termi-
nal elimination half-life (t1/2) after single dose (GeoM
(GeoCV) 3.97 h (18.6%) after HX575 and 4.03 h (25.5%)
after the comparator) and multiple doses (GeoM
(GeoCV) 3.85 h (39.0%) after HX575 and 4.37 h (43.5%)
after the comparator) were similar, suggesting that the
clearance of epoetin was unchanged.
Furthermore, the magnitudes of the Cmax, ss and AUCτ after
multiple doses were similar to the Cmax and AUC0–12 after
single dose. The accumulation ratio for Cmax (GeoM of
Cmax, ss/Cmax) was 1.2 (HX575) and 1.1 (comparator). The
ratio of AUCτ/AUC0–12 was 0.98 (HX575) and 0.89 (com-
parator), suggesting that there was no accumulation with
respect to the extent of exposure.
To compare the relative bioavailability of the epoetin
from HX575 and the comparator, the ratios of the phar-
macokinetic parameters were calculated (Table 3). The
treatment groups were comparable with respect to the
endogenous erythropoietin baseline concentration as
indicated by the ratio and 90% CI of 110% [99.5–
120.2%]. With the exception of the t1/2 ratio, the 90% CIs
Table 1: Demographic characteristics.
Demographic characteristic HX575
(n = 40)
Comparator
(n = 40)
Age (year) Mean 32.6 33.4
SD 7.4 6.9
Range 20–46 20–44
Weight (kg) Mean 78.5 78.9
SD 10.1 9.1
Range 60–98 59–100
Height (cm) Mean 179.9 180.9
SD 6.1 5.7
Range 170–190 166–195
BMI (kg/m2) Mean 24.19 24.07
SD 2.34 2.12
Range 20.3–28.3 20.7–28.4
n = number of subjects receiving treatment, SD = standard deviation.BMC Clinical Pharmacology 2009, 9:10 http://www.biomedcentral.com/1472-6904/9/10
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of the multiple dose ratios fell within the acceptance range
for bioequivalence of 80–125% (Table 3). HX575 was
therefore pharmacokinetically equivalent to the compara-
tor epoetin alfa following multiple intravenous adminis-
trations.
Pharmacodynamics
Both treatment groups had similar baseline Hb concentra-
tions of 14.0 ± 0.6 g/dL (HX575) and 14.0 ± 0.5 g/dL
(comparator) and the mean curves were almost congruent
(Figure 2). The mean Hb concentrations reached maxima
of 15.9 ± 0.8 g/dL (HX575) and 15.9 ± 0.8 g/dL (compa-
rator) after 26 study days. The Hb concentrations had
increased from baseline by 1.87 ± 0.64 g/dL (HX575) and
1.97 ± 0.65 g/dL (comparator) on day 26 and by 1.67 ±
0.55/dL (HX575) and 1.76 ± 0.63 g/dL (comparator) on
day 29. The Hb concentrations did not further increase
after the termination of the treatments.
The AUECHb was very similar for both treatments (Table
4). The AUECHb ratio with its 90% CI fell within the stip-
ulated acceptance range of 96.8–103.2%, indicating that
the two treatments were bioequivalent in this respect.
The mean curves for RBC count were similar for both
treatments (Figure 3), starting at similar baseline counts
(4.73 ± 0.25*106/μL after HX575 and 4.68 ± 0.26*106/μL
after comparator). An increase of RBC counts was
observed seven days after the first administration of both
treatments. Like the Hb concentrations, the further
increase of the mean RBC counts occurred in steps that
were synchronous with the application scheme. The RBC
counts reached identical maxima of 5.14 ± 0.31*106/μL
(HX575) and 5.14 ± 0.30*106/μL (comparator) on study
day 26; the increases were 0.41*106/μL (HX575) and
0.46*106/μL (comparator).
The AUECRBC did not show differences between the treat-
ment groups (Table 4). The AUECRBC ratio and 90% CI fell
within the standard bioequivalence range of 80–125%
(Table 4).
The population mean curves of HCT for the treatments
were almost congruent (Figure 4), with similar baseline
values (40.5 ± 1.8% after HX575 and 40.4 ± .7% after the
comparator). An increase of HCT from baseline was
observed eight days after the first application following a
transient decrease (probably due to blood loss on study
day 1, i.e. baseline). Similar to the Hb concentrations, the
further increase of the mean HCT content occurred in
steps synchronous with the application scheme. The HCT
reached similar maxima of 45.3 ± .2% (HX575) and 45.9
± 2.0% (comparator) on study day 26, which corre-
sponded to a relative increase of about 11%. The
AUECHCT were similar for the two treatments (Table 4).
The AUECHCT ratio and 90% CI fell within the standard
bioequivalence range of 80–125% (Table 4).
The mean curves for Ret count were almost congruent for
both treatments (Figure 5) with similar baseline values
(54.5 ± 12.6*109/L after HX575 and 54.7 ± 17.7*109/L
after the comparator). The increase started with the sec-
ond application and continued until day 10 to a maxi-
mum of 181.9 ± 33.9*109/L (HX575) and 184.7 ±
33.0*109/L (comparator). Thereafter the counts returned
step-wise to 125.6 ± 21.8*109/L (HX575) and 126.1 ±
25.3*109/L (comparator) on day 29. The cumulative
responses of the reticulocytes to the treatments (AUECRET)
Table 2: Mean pharmacokinetic parameters after multiple intravenous epoetin doses.
Treatment AUCτ mIU/mL*h) Cmax, ss (mIU/mL) tmax (h) Ctrough (mIU/mL) t1/2 (h)
HX575 Mean 8422 2189 0.086 9.811 4.14
SD 2419 393.7 0.019 2.728 1.71
Min 4327 1203 0.083 5.565 1.90
Median 7930 2180 0.083 9.174 3.48
Max 19321 3197 0.200 18.61 8.43
GeoM 8153 2153 - 9.486 3.85
GeoCV 25.4% 19.3% - 26.2% 39.0%
Comparator Mean 9224 2262 0.083 9.446 4.74
SD 1850 422.0 0.000 2.438 2.00
Min 4977 1272 0.083 5.020 1.31
Median 9181 2210 0.083 9.161 4.45
Max 13268 3161 0.083 15.77 11.03
GeoM 9036 2222 - 9.141 4.37
GeoCV 21.1% 19.7% - 26.6% 43.5%
AUCτ = area under total concentration curve from 0–36 h at steady state; Cmax, ss = peak serum concentration at steady state; tmax = time to Cmax, 
ss; Ctrough = mean pre-dose trough concentration; t1/2 = terminal elimination half-life; SD = standard deviation; GeoM = geometric mean; GeoCV = 
coefficient of variation of GeoM. Number of subjects analysed: n = 37 (HX575) and n = 39 (comparator).BMC Clinical Pharmacology 2009, 9:10 http://www.biomedcentral.com/1472-6904/9/10
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were similar (Table 4). The variability of this characteristic
was higher than for the RBC counts, but did not differ
between the treatments. The AUECRET ratio and 90% CI
fell within the standard bioequivalence range of 80–125%
(Table 4).
After both treatments the transferrin receptor concentra-
tions increased continuously to more than twice the base-
line value (from 1.36 ± 0.44 to 2.86 ± 0.50 mg/L after
HX575 and from 1.27 ± 0.40 to 3.04 ± 0.50 mg/L after the
comparator). The transferrin concentrations showed only
a minor increase compared to baseline (from 2.59 ± 0.47
to 2.75 ± 0.49 g/L after HX575 and from 2.65 ± 0.35 to
2.71 ± 0.36 g/L after the comparator) and returned to
baseline levels after the termination of the treatments. A
decrease to less than 50% of the baseline value was
observed for the ferritin concentration (from 75.9 ± 52.7
to 29.7 ± 15.8 μg/L after HX575 and from 71.9 ± 74.6 to
29.3 ± 22.6 μg/L after the comparator) and for the iron
concentration (from 19.6 ± 7.1 to 9.7 ± 3.5 μmol/L after
HX575 and from 20.3 ± 8.9 to 8.9 ± 3.8 μmol/L after the
comparator). The concentrations returned to the baseline
values after termination of the treatments. There was no
apparent difference between the treatments.
Safety
A total of 95 adverse events were reported during the
study: 38 events after HX575 compared to 57 events after
Mean serum epoetin concentration-versus-time profiles (± SD) after multiple doses not corrected for baseline epoetin levels Figure 1
Mean serum epoetin concentration-versus-time profiles (± SD) after multiple doses not corrected for baseline 
epoetin levels. 0 h = time of 11th application on study day 24.
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Table 3: Ratio (HX575/comparator), 90% confidence intervals, and ANOVA coefficient of variation of pharmacokinetic parameters 
after multiple epoetin doses.
PK Parameter Method Ratio (%) 90% CI (%) ANOVA-CV (%)
AUCτ MWW-log* 89.2 82.5–96.2 23.3
Cmax, ss MWW-log* 97.5 91.1–104.5 19.5
Ctrough ANOVA-log 103.8 94.0–114.6 26.4
t1/2 MWW-log* 87.8 75.3–100.0 41.4
AUCτ = area under total concentration curve from 0–36 h at steady state; Cmax, ss = peak serum concentration at steady state; Ctrough = mean pre-
dose trough concentration on day 24; t1/2 = terminal elimination half-life; ANOVA-CV = ANOVA coefficient of variation; Method = method used to 
calculate 90% CI (ANOVA or Mann-Whitney-Wilcoxon of log-transformed data). *Significant deviation of the ANOVA residuals from normal 
distribution p < 0.05. The treatments were considered bioequivalent if the ratio and 90% CI fell within the range of 80–125%.BMC Clinical Pharmacology 2009, 9:10 http://www.biomedcentral.com/1472-6904/9/10
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the comparator. This difference was more pronounced for
those events with a suspected relationship to the study
medication (13 in the HX575 group versus 31 in the com-
parator group). However, the clinical relevance of this dif-
ference was considered negligible. Of the events with a
suspected relationship, arthralgia, headache, tiredness
and dizziness were reported most frequently. Anti-epoetin
antibodies were not detected in any subject.
The skin tolerability of both preparations was very good;
the overall incidence of local reactions was below 2.5%.
Skin tolerability of the intravenous HX575 injections
(bruising or inflammation at the injection site was
observed after five out of 798 injections; 0.6%) was
slightly better than that of the comparator (a reaction after
19 out of 827 injections; 2.3%).
Discussion
The study was designed to estimate the relative bioavaila-
bility and to assess bioequivalence with respect to the
pharmacodynamic action of the new epoetin formula-
tion, HX575, compared to a registered epoetin alfa formu-
lation with documented efficacy. The primary
pharmacokinetic parameter was AUCτ. The primary objec-
tive of the study was to assess bioequivalence in terms of
the AUECHb. Furthermore, the safety profiles of the two
treatments were compared.
The investigational products in this study had similar phar-
macokinetic profiles after multiple epoetin doses. The 90%
CIs of the ratios for AUCτ and Cmax, ss fell within the accept-
ance range of 80–125%, indicating that HX575 and the
comparator epoetin alfa were bioequivalent with respect to
the rate and extent of exposure of exogenous epoetin. The
treatments were also bioequivalent with respect to the hae-
matological efficacy, as shown by the AUECHb ratio and
90% CI, which fell within the acceptance range of 96.8–
103.2%. The study results thus consistently demonstrate
that the haematopoiesis following intravenous dosing was
identical after both epoetin formulations. There was no
clinically relevant difference in the safety profiles of HX575
and the comparator epoetin alfa.
The Cmax and AUC obtained in the present study agreed
well with those obtained in comparable studies with
Mean haemoglobin concentration-versus-time profiles during  treatment Figure 2
Mean haemoglobin concentration-versus-time pro-
files during treatment.
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Table 4: Area under the effect curve (AUEC), AUEC ratio (HX575/comparator), 90% confidence intervals and ANOVA coefficient of 
variation over days 1–29 of the study for the AUECs of the haematological parameters.
Haematological parameter HX575 Comparator Ratio (%) 90% CI (%) ANOVA-CV (%)
AUECHb (g/dL*h) – GeoM 10049.4 10064.3 99.9 98.5–101.2 3.6
AUECHb (g/dL*h) – GeoCV 3.5% 3.6% - -
AUECRBC (106/μL*h) – GeoM 3318 3298 100.6 98.5–102.7 5.4
AUECRBC (106/μL*h) – GeoCV 5.5% 5.4% - -
AUECHCT (%*h) – GeoM 28796 28912 99.6 98.2–101.0 3.7
AUECHCT (%*h) – GeoCV 4.1% 3.3% - --
AUECRET (h*109/L) – GeoM 85577 87070 98.3 93.0–103.9 14.5
AUECRET (h*109/L) – GeoCV 13.3% 15.6% - -
GeoM = geometric mean; GeoCV = coefficient of variation of GeoM; CI = confidence interval; ANOVA-CV = ANOVA coefficient of variation. 
Method used to calculate the 90% CI: ANOVA on log-transformed data. The treatments were considered bioequivalent if the ratio and 90% CI of 
the AUEChb fell within the range of 96.8–103.2%. The other parameters were considered bioequivalent if the respective AUEC ratio and 90% CI fell 
within the range of 80–125%. Number of subjects analysed: n = 37 (HX575) and n = 39 (comparator).BMC Clinical Pharmacology 2009, 9:10 http://www.biomedcentral.com/1472-6904/9/10
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healthy subjects, e.g. Halstenson et al. [21] determined an
epoetin alfa baseline-adjusted Cmax of 1796 mIU/mL and
an AUC of 12,499 mIU/mL*h in 18 volunteers after a sin-
gle intravenous dose of 100 mIU/mL.
The magnitudes of the Cmax and AUC after multiple doses
were similar to those after single dose. The accumulation
ratio for Cmax was 1.2 (HX575) and 1.1 (comparator). The
ratio of AUCτ/AUC0–12 (0.98 after HX575 and 0.89 after
the comparator) gives additional evidence that there was
no accumulation with respect to the extent of exposure.
The true accumulation ratio AUC0–36, ss/AUC0–36, sd could
not be estimated as the time concentration profile was not
monitored over a full single dose interval of 36 h. How-
ever, the true value of AUC0–36, ss/AUC0–36, sd must be
smaller than that of AUC0–36, ss/AUC0–12.
The initial pharmacodynamic response after the first
doses showed a similar increase of the RBC and the total
Ret count for both treatments. There was no indication of
any differences between the investigated epoetin formula-
tions with respect to their pharmacodynamic action. The
population mean time pharmacodynamic action curves
for all investigated pharmacodynamic parameters were
congruent.
The increase of the Hb concentrations after repeated doses
of epoetin with 1.67 g/dL (HX575) and 1.76 g/dL (com-
parator) demonstrates that the effect on the haematopoi-
esis in healthy volunteers was comparable with that
observed in patients undergoing haemodialysis [25]. With
the recommended epoetin dose and an optimal iron sub-
stitution, the increase of the Hb concentration should be
1–2 g/dL per month [26].
Conclusion
HX575 and the comparator epoetin alfa were bioequiva-
lent in relation to their pharmacokinetic profiles and their
pharmacodynamic action at steady state drug concentra-
tions following multiple intravenous administrations
with respect to the rate and extent of exposure to ESA. The
multiple intravenous doses of the ESA, HX575 and the
comparator epoetin alfa were well tolerated with no sig-
nificant differences between safety profiles of the treat-
ments. HX575 met the bioequivalence criteria with
respect to the area under the effect curve of Hb produc-
tion, which was the primary pharmacodynamic endpoint
of this study. These results support the conclusion that
HX575, an ESA approved as a biosimilar, and the compa-
rator epoetin alfa, are equally efficacious and may be used
Mean red blood cell count-versus-time profiles during treat- ment Figure 3
Mean red blood cell count-versus-time profiles dur-
ing treatment.
4.2
4.4
4.6
4.8
5.0
5.2
5.4
5.6
5.8
M
e
a
n
 
R
B
C
 
c
o
u
n
t
 
(
x
1
0
6
/
µ
L
)
HX575 (n = 37)
Epoetin alfa (n = 39)
0 5 10 15 20 25 30
Time (days)
Mean haematocrit percentage-versus-time profiles during  treatment Figure 4
Mean haematocrit percentage-versus-time profiles 
during treatment.
36
38
40
42
44
46
48
50
M
e
a
n
 
H
C
T
 
(
%
)
HX575 (n = 37)
Epoetin alfa (n = 39)
0 5 10 15 20 25 30
Time (days)
Mean reticulocyte count-versus-time profiles during treat- ment Figure 5
Mean reticulocyte count-versus-time profiles during 
treatment.
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interchangeably as intravenous therapy for anaemia in
chronic kidney disease.
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